A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.
The guidelines, published in JAMA Oncology, recommend discontinuing routine mammograms for survivors with a life expectancy under five years; considering stopping screening for those with a 5-10-year life expectancy; and continuing mammography for those whose life expectancy is greater than 10 years.
The guidelines will be complemented by printed materials to help survivors gauge their risk of cancer recurring in the breast and weigh the potential benefits and drawbacks of mammography with their health care team.
“The standard recommendation for mammography in breast cancer survivors of all ages has been annual screening,” first author Rachel A. Freedman, of Dana-Farber Cancer Institute, said in a statement. “There has been little guidance on how to tailor screening for older survivors—what role life expectancy, risk of recurrence, patient preferences, or the tradeoffs associated with mammography should play.”
“The result is that the use of mammography for older survivors has been highly inconsistent. With the number of older women who will be diagnosed with breast cancer expected to increase in the coming years, it’s important that we find ways to individualize decisions for each patient’s circumstances and preferences,” Freedman said.
Freedman recruited an 18-member panel of patients and experts from breast cancer primary care, geriatrics, radiology, survivorship, and nursing to review the scientific literature on the risk of in-breast cancer among older breast cancer survivors.
The group conducted a parallel review of research on the benefits and downsides of mammography.
Reassuringly, the literature review confirmed that most older breast cancer survivors had a low risk for breast cancer in either breast—particularly for those who had been treated with hormone-blocking therapy for hormone receptor-positive tumors. The panel estimated older survivors’ risk of developing cancer in the breast over a 10-year period and organized their results by cancer type and treatment.
The review of mammography studies found that although the benefits of screening in older women are not well defined, research suggests mammography offers little to modest clinical benefit for many older women. The main downsides of mammography were false-positives (detection of growths that appear cancerous but turn out not to be), anxiety associated with diagnostic testing, and overtreatment.
Combining the results of these reviews, the panel formulated a series of mammography guidelines for survivors of breast cancer. The guidelines were considered by a group of clinicians and patient advocates and by five clinician focus groups, resulting in several revisions. After further review by the International Society for Geriatric Oncology, the guidelines were refined and finalized.
Because of the low risk that older survivors will develop a cancer in their breast, the lengthy time needed for the small benefits of mammography to be realized, and the persistence of the negative effects of mammography, the new guidelines recommend discontinuing mammography for breast cancer survivors age 75 or older whose life expectancy is under five years.
This holds even for those with a history of higher-risk tumors such as triple-negative or ERBB2-positive. (Life expectancy is estimated by factors such as an individual’s medical history, their degree of functional independence, whether they smoke cigarettes, had a fall in the previous year, and whether they were recently hospitalized).
The guidelines call for consideration of stopping mammography when life expectancy is five to 10 years and continuing annual or biennial mammography when life expectancy exceeds 10 years. For women age 85 and older, whose life expectancy is often under five years, the guidelines recommend ceasing mammography unless an individual is in extraordinary health and has a strong preference to continue testing.
“The purpose of the guidelines is to offer clinicians support for having these conversations with patients and to make a shared, individualized decision for each woman,” Freedman said.
